肿瘤血管生成是指从已存在的微血管上生长出新的毛细血管的过程，为肿瘤的生长、浸润和转移所必需。血管内皮细胞生长因子（VEGF)是肿瘤细胞分泌的最重要的促血管生长因子，通过受体KDR发挥生物学功能。单独阻止受体KDR即可控制VEGF介导的肿瘤的血管生成。细胞因子白介素12（IL-12）可诱导IFN-γ，IP-10的产生，有效地杀伤血管内皮细胞。本研究采用抗新生血管治疗策略， 建立由KDR启动子调控的、腺病毒介导的单纯疱疹病毒胸苷激酶基因系统和含IL-12基因重组逆转录病毒，体外试验评估含KDR启动子驱动的HSV－tk基因重组腺病毒及含有IL–12 的重组逆转录病毒对鼻咽癌血管内皮细胞的杀伤作用，为今后建立稳定的人鼻咽癌细胞株裸鼠模型治疗提供更贴近临床实际的模拟条件，为鼻咽癌的靶向性抗新生血管治疗打下实验基础。

Tumor angiogenesis is a process of growth of new capillaries from microvascular existed, as required for growth, invasion and metastasis of tumor. Vascular endothelial growth factor (VEGF) is secreted by tumor cells, the most important angiogenic growth factor, exerts its biological function through the receptor KDR. A separate block angiogenesis receptor KDR can control the VEGF mediated tumor. Cytokine interleukin 12 (IL-12) can induce IFN- γ, IP-10 production, effectively killing of vascular endothelial cells. In this study, the treatment strategy of anti angiogenesis, establishment of HSV adenovirus mediated by KDR promoter, the thymidine kinase gene and recombinant retrovirus containing IL-12 gene, In vitro evaluation of recombinant HSV adenovirus TK drive containing KDR promoter and IL - containing 12 recombinant retrovirus on nasopharyngeal carcinoma vascular endothelial cells in vitro, simulate conditions closer to the clinical practice for the future establishment of human nasopharyngeal carcinoma cell line in nude mice in treatment of stable, anti newborn for nasopharyngeal cancer targeting vascular treatment of experimental basis.